GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3359)

  • GC73159 structure
    GC73159KTX-582
    CAS: 2573298-13-0
    Purity: >98.00%

    KTX-582 는 효과적인 IRAK4 분해제로서 IRAK4와 Ikaros의 DC50 값은 각각 4nM과 5nM입니다.

  • GC73166 structure
    GC73166U7D-1
    Purity: >99.00%

    U7D-1는 first-in-class의 강력하고 선택적인 USP7 (ubiquitin-specific protease 7) PROTAC 분해제이며, DC50이 33 nM인 RS4;11 cell.

  • GC73168 structure
    GC73168p53 Activator 3
    CAS: 2636839-90-0
    Purity: >95.00%

    p53 Activator 3 (화합물 87A)는 SC150 값이 <0.05 mM인 강력한 p53 활성제이다.

  • GC73188 structure
    GC73188SFI003
    CAS: 2361332-90-1
    Purity: >99.00%

    SFI003은 SRSF3/DHCR24/ROS 축을 통해 CRC 세포 사멸을 추진하고 in vitro와 in vivo에서 모두 강력한 항암 효과를 나타내는 SRSF3억제제이다.

  • GC73199 structure
    GC73199M47
    CAS: 890808-56-7
    Purity: >99.00%

    M47는 크립토크롬 1 (CRY1)을 선택적으로 불안정하게하고 핵 내 크립토 1의 분해를 증가시키는 작은 분자이다.

  • GC73210 structure
    GC73210MTR-106
    CAS: 1639357-93-9
    Purity: >99.00%

    MTR-106 는 강력한 경구 활성 G-쿼드 체인 안정제와 RNA 중합 효소 I 억제제입니다.

  • GC73212 structure
    GC73212TH-6
    CAS: 3031349-25-1
    Purity: >95.00%

    TH-6 는 강력한 HDAC 억제제로서 HDAC1, HDAC2, HDAC3, HDAC6, HDAC8의 IC50은 각각 0.115, 0.135, 0.242, 0.138, 2.120 µM이다.

  • GC73220 structure
    GC73220LSD1-IN-24
    CAS: 4734-59-2
    Purity: >99.00%

    LSD1-IN-24 (복합 3S)는 선별적 LSD1 억제와 IC50 = 0.247 μ M.

  • GC73225 structure
    GC73225ROS-generating agent 1
    CAS: 2369030-41-9
    Purity: >99.00%

    ROS-generating agent 1 (화합물 2c)는 TrxR의 Sec-498잔류물을 공유적으로 변형시켜 ROS를 생성한다.

  • GC73228 structure
    GC73228MS78
    CAS: 3034773-00-4
    Purity: >99.00%

    MS78 는 아세틸화 표적 접합체(AceTAC)로 아세틸화 p53 종양 억제 단백질이다.

  • GC73232 structure
    GC73232PRDX1-IN-1
    Purity: >98.00%

    PRDX1-IN-1 는 PRDX1의 선택적 억제제로서 IC50 값은 0.164 μM입니다.

  • GC73234 structure
    GC73234MY-673
    CAS: 2944459-96-3
    Purity: >98.00%

    MY-673 는 마이크로튜브 단백질 중합을 억제하는 추수선소 결합 비트 억제제(CBSI)입니다.

  • GC73237 structure
    GC73237BWA-522
    CAS: 3042820-12-9
    Purity: >99.00%

    BWA-522 는 AR-FL과 AR-V7에 뚜렷한 분해 작용을 하는 경구 소분자 단백질 표적 접합체(PROTACs)이다.

  • GC73243 structure
    GC73243Nrf2-IN-3
    CAS: 6325-13-9
    Purity: >99.00%

    Nrf2-IN-3 (화합물 R16) 는 Nrf2 억제제입니다.

  • GC73268 structure
    GC73268PH14
    Purity: >99.00%

    PH14은 이중 PI3K/HDAC 억제 IC50 값의 20. 3 nM과 24. 5에 대한 nM PI3K α와 HDAC3, 각각이다.

  • GC73269 structure
    GC73269ABBV-467
    CAS: 2287186-66-5
    Purity: >99.00%

    ABBV-467는 선택적 MCL-1억제제이다 (Ki:<0.01 nM).

  • GC73272 structure
    GC73272PARP-1-IN-3
    CAS: 2976342-33-1
    Purity: >99.00%

    PARP-1-IN-3 페닐메틸아미드 유도체는 PARP-1 억제제로서 PARP-1과 PARP-2의 IC50 값은 각각 0.25nM과 2.34nM이다.

  • GC73274 structure
    GC73274EGFR T790M/L858R-IN-2
    CAS: 2955607-40-4
    Purity: >99.00%

    EGFR T790M/L858R-IN-2는 EGFRT790M/L858R, EGFR WT에 대해 각각 3.5, 1290 nM의 IC50 값을 갖는 강력하고 선택적인 EGFRT790M/L858R 억제제입니다.

  • GC73275 structure
    GC73275PD-L1-IN-2
    CAS: 2894733-91-4
    Purity: >98.00%

    PD-L1-IN-2는 PD-L1을 억제함으로써 잠재적인 종양 면역 물질입니다.

  • GC73288 structure
    GC73288CDK8-IN-13
    CAS: 918523-75-8
    Purity: >98.00%

    CDK8-IN-13는 강력하고 선택적이고 경구 투여 가능한 CDK8 억제제로 IC50 값이 51.9nM이다.

  • GC73294 structure
    GC73294F5446
    CAS: 2304465-89-0
    Purity: >99.00%

    F5446 (화합물 1)는 SUV39H1 금속 전이 효소의 선택적 소분자 억제제입니다.

  • GC73309 structure
    GC73309Anti-melanoma agent 1
    CAS: 2418579-17-4
    Purity: >99.00%

    Anti-melanoma agent 1 (화합물 5m)은 항 흑색종 제제이며 세포 사멸을 유도합니다.

  • GC73311 structure
    GC73311STAT3-IN-13
    CAS: 2248552-86-3
    Purity: >99.00%

    STAT3-IN-13 (화합물 6f)는 강력한 STAT3억제제이다.

  • GC73313 structure
    GC73313PI3Kα-IN-9
    CAS: 2715287-67-3
    Purity: >99.00%

    PI3Kα-IN-9 (화합물 27) 는 선택적이고 장기적이며 경구 활성인 PI3K 알파 억제제로서 PI3K 알파, PI3K 감마, PI3K 델타, PI3K 베타에 대한 IC50 값은 각각 4.4, 128, 146, 153 nM이다.